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Abstract. Handajani NS, Dharmawan R. 2009. Effect of VCO to leucocyte differential count, glucose levels and blood creatinine of 
hyperglycemic and ovalbumin sensitized Mus musculus Balb/c. Nusantara Bioscience 1: 1-8. Chemical medicines and insulin can 
decrease glucose blood level on hyperglycemic patients with macro vascular side effect. Diabetes and allergy incidences are influenced 
by quality and quantity of leucocytes. Lauric acid within VCO reports decreased glucose blood level of diabetes and some allergy 
incidents. The purpose of the study is to know the effect of VCO on glucose blood level, differential leucocytes count and creatinine 
blood level on hyperglycemic and normoglicemic ovalbumin sensitized mice. Forty five (45) male (mice) of Mus musculus Balb/c with 
average weight of 35 g are divided into 9 groups with 5 repetitions, those are 4 non alloxan groups and 5 alloxan induced hyperglycemic 
groups. On 22nd day to 36th day they are sensitize to ovalbumin as allergen. Blood sample was obtained by orbital vena using heparin as 
anti coagulant in order measuring glucose blood level by GOD method to 6 times, on 1st, 4th, 18th, 22nd, 32nd and 37th days, then are 
tested by ANOVA followed by DMRT 0.05. On 37th day, differential leucocytes are determined, blood level are counted, and then 
compared to normal value. The result of this study were that within differential leucocytes count of hyperglycemic mice, neutrophile 
percentage were much lower than the normal value (3.22%), and lymphocyte percentage were much higher than the normal value 
(94.54%). Consumed 0.003 mL/35 g VCO more 18 days decreased glucose blood level on hyperglycemic mice, decreased basophile 
percentage of ovalbumin sensitized mice, normalized neutrophile percentage no increased creatinine blood level.  
Key words: VCO, hyperglycemic, allergy, leucocytes differential count, blood creatinine. 
Abstrak. Handajani NS, Dharmawan R. 2009. Pengaruh VCO terhadap hitung jenis leukosit, kadar glukosa dan kreatinin darah Mus 
musculus Balb/c hiperglikemi dan tersensitisasi ovalbumin. Nusantara Bioscience 1: 1-8. Obat-obatan kimia dan insulin dapat 
menurunkan kadar glukosa darah pada pasien dengan efek samping hiperglikemi makro vaskular. Diabetes dan insiden alergi 
dipengaruhi kualitas dan kuantitas leukosit. Asam laurat dalam VCO dilaporkan menurunkan tingkat glukosa darah pada kejadian 
diabetes dan beberapa insiden alergi. Tujuan penelitian ini adalah mengetahui pengaruh VCO pada tingkat glukosa darah, diferensial 
leukosit dan kadar kreatinin pada mencit hiperglikemi dan normoglicemic tersensitisasi ovalbumin. Empat puluh lima (45) mencit Mus 
musculus Balb/c jantan dengan berat rata-rata 35 g dibagi menjadi 9 kelompok  dengan 5 ulangan, yaitu 4 kelompok non aloksan dan 5 
kelompok hiperglikemi yang diinduksi aloksan, Pada hari ke-22 sampai ke-36, mereka disensitisasi dengan ovalbumin sebagai penyebab 
alergi. Sampel darah diperoleh dari vena orbital menggunakan heparin sebagai anti koagulan, kadar glukosa darah diukur dengan 
metode GOD sebanyak 6 kali, pada hari ke-1, 4, 18, 22, 32 dan 37, kemudian diuji dengan ANAVA yang diikuti oleh DMRT 0,05 untk 
mengetahui tingkat perbedaan antar perlakuan. Pada hari ke-37, diferensial leukosit dan tingkat kreatinin darah ditentukan, lalu 
dibandingkan dengan nilai normal. Hasil penelitian menunjukkan bahwa dalam hitungan diferensial leukosit mencit hiperglikemi, 
persentase neutrofil jauh lebih rendah daripada nilai normal (3.22%), dan persentase limfosit jauh lebih tinggi daripada nilai normal 
(94.54%). Konsumsi 0.003 mL/35 g VCO lebih dari 18 hari menurunkan kadar glukosa darah pada mencit hiperglikemi, menurunkan 
persentase basophile pada mencit tersensitisasi ovalbumin, normalisasi persentase neutrophile tidak meningkatkan tingkat kreatinin darah.  
Kata kunci: VCO, hiperglikemia, alergi, hitungan diferensial leukosit, kreatinin darah. 
INTRODUCTION 
Diabetes mellitus is a disease of the pancreatic 
endocrine hormones, including insulin and glucagons. This 
was due to inadequate insulin activity so that the amount of 
insulin secretion is reduced (Suharmiati 2003) or a 
response decrease in peripheral tissue to insulin (insulin 
resistance) and a decrease in the ability of pancreatic beta 
cells to secrete insulin in response to glucose load. The 
main manifestations include disorders of lipid metabolism, 
carbohydrate and protein which in turn stimulate the 
conditions of hyperglycemia. The condition of 
hyperglycemia will develop into diabetes mellitus with 
various forms of complications manifestation (Unger and 
Foster 1992; Nugroho 2006). According to the UKPDS 
(1999), although the sulfonylurea drugs and insulin can 
lower blood glucose levels, but it can cause macrovascular 
problems. Because glucose is very important in 
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lymphocytes metabolism, the Diabetes can also cause 
characteristic changes in lymphocyte metabolism (Otton et 
al. 2002), which in turn can stimulate the apoptosis 
lymphocyte (Otton et al. 2004). Research of Alba-Loureiro 
et al. (2006) showed that diabetes also causes the 
characteristic on neutrophile function and metabolism of 
white rats. 
Today, allergic is interpreted as immunologic reaction 
to antigens unreasonably or inappropriately in individuals 
who have previously sensitized by the antigen in question, 
so that the antigen is called an allergen. Ovalbumin, an 
allergenic protein that is found in white egg, can often 
cause allergic reactions in children (Endaryanto and 
Harsono 1996). Two processes that mark the occurrence of 
allergic process are exocytose of granule contents such as 
histamine and the induction of the formation of mediators 
that stimulate the formation of prostaglandins and 
leukotrienes that have a direct impact on the local tissue 
(Kresno 2001). 
All this time, the use of VCO (Virgin Coconut Oil) for 
cases of diabetes and allergies are empirically much done, 
so the author wants to prove a reduction of blood glucose 
levels in hyperglycemia mice (Mus musculus Balb/c) with 
the treatment of VCO. Given the role of several types of 
leukocytes between the cases of diabetes and allergies, so 
in this study, it also should be noted that the VCO is 
potential for the vulnerability of normal and hyperglycemia 
mice on allergen exposure by viewing the leukocyte 
counts.  
The consumption of nutritious substances that are 
expected to resolve a complaint needs to be watched out as 
the negative impacts may arise as a side effect. Therefore, 
it should be tested for the presence or absence of the rise of 
blood creatinine levels indicating the normality status of 
renal function physiologically, because the inability to 
excrete creatinine as a component of urine, so, in large 
numbers, it flows back into the bloodstream above its 
normal values. 
Based on the background of the problems above, the 
purpose of this study are: (i) to examine the effect of VCO 
on blood glucose levels in mice (M. musculus) Balb/c 
hyperglycemia, (ii) to know the leukocyte counts of mice 
hyperglycemia, (iii) to investigate the VCO effect on 
leukocyte counts mice which are exposed to ovalbumin, 
(iv) the effect of VCO on leukocyte counts mice 
hyperglycemia which are exposed to ovalbumin, (v) the 
effect of VCO on levels of blood creatinine of mice in 
efforts to achieve normal glichemia conditions and 
protection against exposure to ovalbumin. 
MATERIALS AND METHODS 
Time and place  
This research was conducted in October-November 
2007. The Maintenance and the checking of blood sugar 
levels and creatinine in mice were conducted in LP3HP-
LPPT Gadjah Mada University, Yogyakarta. 
Material  
VCO is obtained from PT Prima Solutions Medika 
Jakarta, 45 mice (Mus musculus BaIb/c) which are 2-3 
months old and male with an average body weight of 35 g 
are obtained from LP3HP-LPPT Gadjah Mada University, 
Yogyakarta. Alloxan monohydrate (SIGMA), 
glibenclamide (Kalbe Farma), ovalbumin (SIGMA), pellets 
are used to feed the mice and tap water is as drink.  
Procedures 
Before the treatment, 45 mice Balb/c which are 2-3 
months old and male with an average body weight of 35 g 
are acclimated to suit with laboratory conditions, then they 
are divided into 9 groups. They are fed with pellets and 
gave drink with tap water, ad libitum. Then the following 
works are performed:  
Determination of dosage and injection of alloxan. 
Alloxan dose given to monkeys (Macaca fascicularis) after 
being converted to white rats weighing 200 g is 35 mg/200 
g BW (Widyastuti et al. 2005). For mice weighing 35 g is 
35/200x35 mg = 6.125 mg/35 g BW. For injection, the 
alloxan is dissolved in 0.5 mL of distilled water.  
Determination of dosage and the oral application of 
glibenclamide. The dose of glibenclamide in humans is 5 
mg/day/70 kg BW (Tjay and Rahardja 2007), then 
converted in mice = 35/70000 x 5 mg = 0.00025 mg/day 
/35 g BW and for every application, it is dissolved with 0.5 
CMC 1%.  
Determination of dosage and the application of VCO. 
VCO is given to the human therapeutic dose is generally 3 
tablespoons or 45 mL/day (Dayrit, 2000), when converted 
in mice, it is 35/70.000x45 = 0.00225 mL/day /35 kg BW. 
In this study, the doses are given in 2 variations, dose I = 
0.002 mL/day and dose II = 0.003 mL/day.  
Determination of blood glucose levels. Blood glucose 
level was determined with the GOD-PAP method 
(Enzymatic Photometric Test) which is the method of 
photometric measurement with spectrophotometer 
(Widowati et al. 1977). The measurements are taken 6 
times during the study, day 1 (just before alloxan 
treatment), day 4, day 18, day 22, day 32 and day 37 (just 
before the sacrifice). 
Determination of dose and way of allergen injection. 
Determination of allergen dose and way of allergen 
injection refer to the work of Diding (2007) who managed 
to create mice with an average weight of 17.5 mg to have 
an allergy on its digestive system. This study used mice 
with an average weight of 35 mg, so every injection can be 
converted into 2X of the initial dose, with the protocol as 
follows: On day 22 sensitization of mice by injection of 
0.30 mL ovalbumin out of 2.5 mg ovalbumin in 7.75 mL of 
Al(OH)3 in intra-peritoneal way. The re-sensitization is 
with the same solution and the same way on day 28. then, 
on day 32-34 consecutively the mice were re-sensitized by 
giving a solution of 0.30 mL ovalbumin of 2.5 mg 
ovalbumin in 2.5 mL of PBS orally.  
Preparations of blood smear and determination of 
leukocyte count using Romanowski method. The bloods 
are dropped on the surface of glass objects then they are 
made into smears/blood film. Furthermore, they are air-
dried for a few minutes, and then they are dropped with 
methyl alcohol, and left untouched for 5 minutes. 
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Furthermore, the preparations are lifted and placed in 1-2% 
of Giemsa dye solution for 30 minutes. Finally, the 
preparations are removed from the dye solution and washed 
with water, and carefully dried with a tissue, and then they 
are ready to be observed under microscope (Suntoro 1983). 
After all form of leukocytes is observed under microscope 
with 10x100 magnification, with emersion oil paced on the 
surface of the smear preparations. Furthermore, the 
percentage of each type of leukocytes from 100 leukocytes 
found in every preparation is counted (Fox 1990).  
Calculation of blood creatinine levels. Decrease in 
renal physiological function can be ascertained from the 
increased levels of blood creatinine. Blood creatinine levels 
were measured with a spectrophotometer of photometric 
system based on method of Daffe. 
The experimental design  
This study used 45 mice (M. musculus Balb/c) which 
are divided into 9 groups. The blood glucose measurements 
were performed 6 times and then a Completely 
Randomized Design was carried out, using 9 kinds of 
treatments with five replications at each treatment, as follows: 
A. Treatment of normal controls: mice were given food 
and drink each day ad libitum without any treatment 
until the end of the study.  
B. Treatment of non-alloxan, CMC and ovalbumin 
sensitization: on day 4 mice were given with 0.5 mL of 
1% CMC, orally every day until the end of the study. 
Ovalbumin sensitization was started on day 22-36.  
C. Non alloxan treatment, dose I of VCO and ovalbumin 
sensitization: on day 4 mice were given orally with 
VCO 0.002 mL/35 g BW every day until the end of the 
study. Ovalbumin sensitization was started from day 
22-36.  
D. Treatment of non-alloxan, VCO dose II and ovalbumin 
sensitization: on day 4 mice were given orally with 
VCO 0.003 mL/35 g BW every day until the end of the 
study. Ovalbumin sensitization was started from day 
22-36.  
E. Treatment of hyperglycemia control: on day 1 mice 
were injected with alloxan 6.125 mg/35 g BW 
subcutaneous, then they were let to be fed and drank ad 
libitum without any treatment until the end of the study.  
F. Treatment of alloxan, CMC and ovalbumin sensitization: 
on day 1 mice were injected subcutaneously with 
alloxan 6.125 mg/35 g BW, then on day 4-36 were 
given with 0.5 mL of 1% CMC. Ovalbumin sensitized 
was begun at day 22-36.  
G. Treatment of alloxan, VCO dose I, ovalbumin 
sensitization: on day 1 mice were injected 
subcutaneously with 6.125 mg/35 g BW, then on days 
4-36 were given with VCO 0.002 mL/35 g BW orally 
and ovalbumin sensitization began on day 22-36.  
H. Treatment of alloxan, VCO dose II, ovalbumin 
sensitization: on day 1 mice were injected 
subcutaneously 6.125 mg/35 g BW, then on day 4-36 
were given with 0.003 mL/35 g BW of VCO orally and 
ovalbumin desensitization began on day 22-36.  
I. Treatment of alloxan, glibenclamide and ovalbumin 
sensitization: on day 1 mice were injected 
subcutaneously with alloxan 6.125 mg/35 g BW, then 
on day 4-36 was given orally with 0.0025 mg of 
glibenclamide in 1% CMC and ovalbumin sensitization 
began on day 22-36. 
Data analysis  
Quantitative data of blood glucose levels were analyzed 
using the ANOVA (Analysis of Variance) and if there are 
significant differences, then it is followed by the DMRT 
test (Duncan's Multiple Range Test) at the significance 
level of 5% to determine the significance differences 
among the treatments. So the VCO effect in decreasing the 
blood glucose levels in hyperglycemic mice can be 
detected. Quantitative data of leukocyte differential were 
obtained by counting each type of leukocytes in each 
treatment group. And then, the data mean were compared 
with differential of normal leukocyte, according to Smith 
and Mangkoewidjojo (1988) and Jacoby and Fox (1984) to 
compare the leukocyte differential of mice in conditions of 
hyperglycemia, hyperglycemia that have been treated with 
the VCO, and hyperglycemia which is exposed to 
allergens, mice exposed to VCO which is then exposed to 
allergens and normal leukocyte differential in mice, so that 
can know the relationship between hyperglycemia, VCO 
and the development of allergy immunology. Quantitative 
data average blood creatinine levels of each treatment 
group is compared with the normal rate according to 
Jacoby and Fox (1984), so the effect of VCO treatments on 
the function status of renal physiology can be known.  
RESULTS AND DISCUSSION  
Blood Glucose Levels (BGL)  
From the results, the state/condition of blood glucose 
levels data can be obtained as shown in Table 1 and Figure 
1: the Mean of Blood Glucose Levels (BGL) of all 
treatment, measurement 1 to measurement 6, Figure 2: the 
Mean of BGL of non alloxan groups, measurements 1 to 6 
and, Figure 3: Mean BGL of alloxan groups, measurement 
1 to 6. The data obtained is analyzed by analysis of 
variance (ANOVA) one way and when there are significant 
difference, it is followed by Duncan test (DMRT) with 
significance level of 5% to determine the real differences 
among the treatments.  
The first measurement of average blood glucose level 
on day 1 was started just before the injection of alloxan. 
The mean blood glucose levels of 45 mice were classified 
into 9 treatment groups. Figure 1 shows that there are no 
significant differences of the blood glucose levels of all 
treatment groups from A to I. It means that between groups 
which were not given with alloxan and the group which 
were given with alloxan showed no significant difference, 
namely in a range of 61.40 to 71.80 mg/dl. This is because 
all the mice used were in normal-glychemia and relatively 
similar. 
Figure 1 shows the measurement 2 (day 4), all 
treatment groups, which were given alloxan or not, had an 
increasing in blood glucose levels, although the non 
alloxan groups were not statistically significant compared 
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to levels at the beginning of treatment. The increase in non 
alloxan groups allegedly was due to stress because of the 
treatment of grouping in a different cage from its usual 
cage. Stress conditions will stimulate the sympathetic 
nervous system for the adrenal medulla to secrete the 
epinephrine hormone which causes the increase in blood 
glucose levels (Guyton and Hall 2008). The same was 
experienced by mice in the groups treated with alloxan. 
In the 3rd measurement (day 18), non alloxan groups 
has blood glucose levels that can be said to be stable, ie 
average maximum of about 100 mg/dl. The difference with 
the alloxan group is so contrast. This is because all of them 
had an increase in blood glucose levels significantly. 
On day 1, shortly after the measurement of blood 
glucose levels, the groups were treated with alloxan. 
Alloxan plays a role in pancreatic beta cells that produce 
insulin and selectively killing these cells (Suharmiati 2003; 
Guyton and Hall 2008). The destruction of pancreatic beta 
cells causes the quantity and or quality of insulin disturbing 
the smooth transport of glucose from the blood into the 
tissues; it causes the glucose pile up in the blood, causing 
an increase in levels (hyperglycemia). 
The 4th measurements (day 32), the average of blood 
glucose level of groups of mice induced with alloxan had a 
significant reduction. The same blood glucose levels found 
in group H (alloxan, VCO dose II, ovalbumin) and group I 
(alloxan, glibenclamide, ovalbumin), although it did not 
reach the previous level which was not significantly 
different from the level in the initial treatment, but giving a 
dose VCO 2 after 18 days gives the same effect with the 
provision of glibenclamide, which lowers blood glucose 
levels. According Tjay and Rahardja (2007), glibenclamide 
is one oral antidiabetic drug including sulfonylurea. 
Sulfonylurea drugs play a role in stimulating beta cells of 
Langerhans islands, so that insulin secretion is increased, 
besides that it also can increase the sensitivity of beta cells 
for blood glucose levels through its influence on glucose 
transport proteins. There are indications that these drugs 
also improve the target organ of insulin and decrease 
absorption of insulin by the liver. While in group H 
(alloxan, VCO dose II, ovalbumin), a decline in blood 
glucose levels happened after the oral provision of VCO at 
a dose of 0.003 mL/35 g BW every day for 18 days. This 
was because of the VCO makes an improvement of 
metabolic activity. MCFAs in the VCO which particularly 
are monolauric can reduce protein catabolism in 
hypercatabolic status, and they can serve as a protein sparer 
which prevents oxidation of amino acids to produce 




Blood glucose levels day by 
1 (day-1) 2 (day-4) 3 (day-18) 4 (day-22) 5 (day-32) 6 (day-37) 
mg/dl mg/dl % changes mg/dl % changes mg/dl % changes mg/dl % changes mg/dl % changes
Non alloxan 
A 71,600a  96,600abc + 34,9 108,600a + 51,7 119,000ab + 66,2 137,000ab + 91,3 69,000a -3,6 
B 61,400a  79,200ab +29 110,000a +79,2 82,000a +33,6 78,800 a +28,3 92,800ab +51 
C 67,200a  66,400a -1,2 93,200a +38,7 75,200a +12 86,400a +28,6 101,600ab +51,2 
D 61,400a 124,200abc + 102 87,800a + 43 113,000ab + 84 79,400a + 29,3 97,200ab +58,3 
Alloxan             
E 69,600a 159,000c +128,4 157,800ab +126,7 160,800bcd +131 156,600ab +125 179,200c +157,5 
F 71,800a 142,000bc +97,8 222,000bc +209,2 128,000abc +78,3 132,200ab +84 150,200bc +109 
G 67,200a 158,800c +136 338,000de +403 205,400d +205,7 220,200b +227,7 230,200c +242,6 
H 64,400a 122,800abc +90,7 299,800cd +365,5 168,200bcd +161,2 104,200a +61,8 200,200c +210,9 
I 61,800a 298,800d +383,5 413,600d +413,6 177,000cd +186,4 162,200ab +162 191,200c +209,4 
Note: The number followed the same superscript letter within a column indicate no significant difference between treatments (p> 0.05). 
A: normal control group (non-alloxan, non-allergen), B: The treatment of non alloxan, CMC and allergens/ovalbumin, C: Treatment of 
non alloxan, VCO dose I and allergens/ovalbumin, D: Treatment of non alloxan, VCO II dose and allergen/ovalbumin, E: The control 
group alloxan/hyperglycemia (alloxan, non-allergen), F: The treatment of alloxan, CMC and allergens/ovalbumin, G: Treatment of 
alloxan, VCO dose and allergen/ovalbumin, H: Treatment of alloxan, VCO dose II and allergens/ovalbumin, I: Treatment alloxan, 







A B C 
Figure 1. Blood Glucose Levels of 1 to 6 repetised measurement. A. All treatment, B. Non-alloxan measurement, C. Alloxan 
measurement. Note: Description of A to I are similar to Table 1. 
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energy, and can also provide a protein into the tissues. The 
supply of network protein stimulates the secretion of 
glucagon which activates adenil cyclase that will produce 
cyclic AMP, so the phosphorylation for the processes of 
normal cell metabolism is activated, such as the repairing 
of gland secretion and enzymes activity, hormones, and of 
their receptors (Guyton and Hall 2008). In this case, it is 
assessed that there was an increase in insulin sensitivity 
hormones and in tissues of insulin receptor, so the supply 
of glucose into the tissue was normal. The other insulin 
functions are also normal, so that high blood glucose levels 
could be lowered. 
In group G (alloxan, VCO dose I, ovalbumin), the same 
mechanism with the group H (alloxan, VCO dose II, 
ovalbumin) occurred though the decrease was not as much 
as dose of VCO 2 group. The mechanism was assumed to 
be the same. In the normal group or the control solvent, 
decrease blood glucose levels occurred, although there was 
no substance that could act as healers, including group E 
(alloxan, non-therapeutic, non ovalbumin) and group F 
(alloxan, CMC, ovalbumin). This was due to the recovery 
levels of the hormone epinephrine in experimental mice as 
the response of the body to restore its normal conditions. 
Therefore, 1% CMC solution was only used as a 
hydrophilic gel drug compounds that were nontoxic, were 
not digested and not absorbed by the individual (Tjay and 
Rahardja 2007), so it does not affect changes in blood 
glucose levels. Only the H group (alloxan, VCO dose II, 
and ovalbumin) is steadily declining blood glucose levels 
until day 32nd, but rose again on day 37th, after ovalbumin 
sensitization protocol is complete. This is because, despite 
improved metabolic activity with the VCO, due to the 
body's response to ovalbumin which acts as allergens, so 
that blood glucose levels which had increased because of 
damage to pancreatic beta cells selectively, was damaged 
again, although not fatal. 
In groups of non alloxan, the rise of blood glucose 
levels that occurred is assumed because of stress. The 
decline did not happen simultaneously, it was because the 
response of the body to restore normal conditions of each 
group was also influenced by the initial conditions and the 
given therapeutic as well as the body's response to 
allergens given. Three non-alloxan groups except group A 
(non-alloxan, non-therapeutic, non ovalbumin) decreased 
maximally and reached levels which were not significantly 
different from day 32nd, Groups C and D which were given 
VCO had decreased first, due to the improvement of 
metabolic activity. In group A, a new decline occurred on 
day 32nd and continued to decline, it was because there was 
no influence in the body, including allergens. 
Determination of leukocyte differential 
Data on the average percentage of each leukocyte type 
of all treatment groups is shown in Table 2. Data average 
percentage of each leukocyte type of each treatment group 
is compared to its normal standard of mice according to 
Smith and Mangkoewidjojo (1988) and according to 
Jacoby and Fox (1984). 
The first measurement of average blood glucose level 
on day 1 was started just before the injection of alloxan. 
The mean blood glucose level of 45 mice was classified 
into 9 treatment groups. Figure 1 showed that there are no 
significant differences of the blood glucose levels of all 
treatment groups from A to I. It means that between groups 
which were not given with alloxan and the group which 
were given with alloxan showed no significant difference, 
namely in a range of 61.40 to 71.80 mg/dl. This is because 
all the mice used were in normal-glychemic and relatively 
similar. 
Figure 1 shows the measurement 2 (day 4), all 
treatment groups, which were given alloxan or not, had an 
increasing in blood glucose levels, although the non 
alloxan groups were not statistically significant compared 
to levels at the beginning of treatment. The increase in non 
alloxan groups allegedly was due to stress because of the 
treatment of grouping in a different cage from its usual 
cage. Stress conditions stimulated the sympathetic nervous 
system for the adrenal medulla to secrete the epinephrine 
hormone which caused the increase in blood glucose levels 
(Guyton and Hall 2008). The same was experienced by 
mice in the groups treated with alloxan. 
In the 3rd measurement (day 18), non alloxan groups 
had blood glucose levels that can be said to be stable, ie 
average maximum of about 100 mg/dl. The difference with 
the alloxan group is so contrast. This is because all of them 
had an increase in blood glucose levels significantly. 
On day 1, shortly after the measurement of blood 
glucose levels, the groups were treated with alloxan. 
Alloxan plays a role in pancreatic beta cells that produce 
insulin and selectively killing these cells (Suharmiati 2003; 
Guyton and Hall 2008). The destruction of pancreatic beta 
cells causes the quantity and or quality of insulin disturbing 
the smooth transport of glucose from the blood into the 
tissues; it causes the glucose pile up in the blood, causing 
an increase in levels (hyperglycemia). 
The 4th measurements (day 32), the average of blood 
glucose level of groups of mice induced with alloxan had a 
significant reduction. The same blood glucose levels found 
in group H (alloxan, VCO dose II, ovalbumin) and group I 
(alloxan, glibenclamide, ovalbumin), although it does not 
reach the previous level which is not significantly different 
from the level in the initial treatment, but giving a dose 
VCO 2 after 18 days gives the same effect with the 
provision of glibenclamide, which lowers blood glucose 
levels. According Tjay and Rahardja (2007), glibenclamide 
is one oral antidiabetic drug including sulfonylurea. 
Sulfonylurea drugs play a role in stimulating beta cells of 
Langerhans islands, so that insulin secretion is increased, 
besides that it also can increase the sensitivity of beta cells 
for blood glucose levels through its influence on glucose 
transport proteins. There are indications that these drugs 
also improve the target organ of insulin and decrease 
absorption of insulin by the liver. While in group H 
(alloxan, VCO dose II, ovalbumin), a decline in blood 
glucose levels happened after the oral provision of VCO at 
a dose of 0.003 mL/35 g BW every day for 18 days. This is 
because of the VCO makes an improvement of metabolic 
activity. MCFAs in the VCO which particularly are 
monolauric can reduce protein catabolism in hypercatabolic 
status, and they can serve as a protein sparer which 
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prevents oxidation of amino acids to produce energy, and 
can also provide a protein into the tissues. The supply of 
network protein stimulates the secretion of glucagon which 
activates adenil cyclase that will produce cyclic AMP, so 
the phosphorylation for the processes of normal cell 
metabolism is activated, such as the repairing of gland 
secretion and enzymes activity, hormones, and of their 
receptors (Guyton and Hall 2008). In this case, it is 
assessed that there was an increase in insulin sensitivity 
hormones and in tissues of insulin receptor, so the supply 
of glucose into the tissue was normal. The other insulin 
functions were also normal, so that high blood glucose 
levels could lowered. 
In group G (alloxan, VCO dose I, ovalbumin), the same 
mechanism with the group H (alloxan, VCO dose II, 
ovalbumin) occurred though the decrease was not as much 
as dose of VCO 2 group. The mechanism is assumed to be 
the same. In the normal group or the control solvent, 
decrease blood glucose levels occurred, although there was 
no substance that could act as healers, including group E 
(alloxan, non-therapeutic, non ovalbumin) and group F 
(alloxan, CMC, ovalbumin). This is due to the recovery 
levels of the hormone epinephrine in experimental mice as 
the response of the body to restore its normal conditions. 
Therefore, 1% CMC solution was only used as a 
hydrophilic gel drug compounds that were nontoxic, were 
not digested and not absorbed by the individual (Tjay and 
Rahardja 2007), so it does not affect changes in blood 
glucose levels. Only the H group (alloxan, VCO dose II, 
and ovalbumin) is steadily declining blood glucose levels 
until day 32nd, but rose again on day 37th, after ovalbumin 
sensitization protocol is complete. This is because, despite 
improved metabolic activity with the VCO, due to the 
body's response to ovalbumin which acts as allergens, so 
that blood glucose levels which had increased because of 
damage to pancreatic beta cells selectively, was damaged 
again, although not fatal. 
In groups of non alloxan, the rise of blood glucose 
levels that occurred is assumed because of stress. The 
decline did not happen simultaneously, it was because the 
response of the body to restore normal conditions of each 
group was also influenced by the initial conditions and the 
given therapeutic as well as the body's response to 
allergens given. Three non-alloxan groups except group A 
(non-alloxan, non-therapeutic, non ovalbumin) decreased 
maximally and reached levels which were not significantly 
different from day 32nd, Groups C and D which were given 
VCO had decreased first, due to the improvement of 
metabolic activity. In group A, a new decline occurred on 
day 32nd and continued to decline, it is because there is no 
influence in the body, including allergens. 
The differential of leukocyte of group A as control 
(non-alloxan, non-therapeutic, non ovalbumin) was: 
1.140% of neutrophils; 90.76% of lymphocytes, 1.52% of 
monocytes 0.22% of eosinophils and 3.00% of basophils. 
All percentage of neutrophile of groups with treatment is 
less than the normal standard by Smith and 
Mangkoewidjojo (1988) and/or according to Jacoby and 
Fox (1984), except in group H (alloxan, VCO 0.003 mL/g 
BW, ovalbumin) which has a normal percentage. 
Furthermore, all lymphocyte percentage of groups with 
treatment is high above normal standards according to 
Smith and Mangkoewidjojo (1988) and/or according to 
Jacoby and Fox (1984), except in group F which has a 
normal percentage. All the percentage of monocytes is 
normal, except in group D (non-alloxan, VCO 0.003 mL/g 
BW), most of the eosinophils percentage in groups with 
treatment is less than the normal percentage. Percentage of 
basophils is higher than normal standards, except for 
groups C, D, E, G, H, and I. 
From the above data, it is estimated that basically in 
animal studies, there has been immunological defense 
mechanism which is likely due to a viral infection. Because 
according to Burkitt et al. (1995), an increased number of 
lymphocytes is generally a marking of a viral infection. 
Neutrophil percentage far below the percentage of normal, 
it also supports the allegation. According to Price and 
Wilson (2006), neutropenia can be caused by disorders of 
neutrophil formation or the formation of ineffective 
neutrophil due to hipoplastic or aplastic anemia caused by 
cytotoxic drugs, the presence of toxic substances and viral 
infections, starvation and replacement by normal bone 
marrow by malignant cells, as in leukemia. Since 
lymphocytes have a central role in all immunological 
defense mechanisms. The increasing percentage of 
basophiles is supposed due to the induction of sensitized 
lymphocytes to respond to antigens or environmental 
allergens that are less profitable. According to Price and 
Wilson (2006), basophiles and mast cells have a membrane 
receptor which is very typical for this segment of Fc&IgE 
produced by plasma cells as antigen/allergen environment. 
Burkitt et al. (1995) also states that basophiles are 
responsible primarily to give an allergic reaction and 
antigen by releasing chemicals histamine that causes 
inflammation. According to the authors, the high 
percentage of basophiles in these groups is as a respond to 
environmental antigens that arise due to endogenous 
viruses that infected him. The percentage of neutrophil on 
group H (alloxan, VCO 0.003 mL/g BW, ovalbumin) 
occupies the normal range according to Smith and 
Mangkoewidjojo (1988) or by Jacoby and Fox (1984) 
In the study, mice groups were suspected of suffering 
from a viral infection, but with the consumption of VCO, 
the reduction of virus amount is assumed to occur because 
of the MCFAs role, mainly mono laurin, through its lipid 
membrane, so the percentage of its neutrophil is normal, 
and this will improve the immunologic status of these mice 
groups. These groups also had a normal percentage of 
basophils. Basophiles are primarily responsible for giving 
an allergic reaction and histamine release by antigen 
chemical that causes inflammation. Basophiles and mast 
cells have a membrane that is very specific for the segment 
of IgE and Fc which is generated by cells plasma as 
response to a number of environmental allergens. The 
exposure of allergens causes the formation of bridges 
between the adjacent IgE molecules that trigger 
evisceration of granule/degranulation appropriately. So the 
release of histamine and other vasoactive mediators is 
responsible for the occurrence of acute hypersensitivity 
reactions to allergic rhinitis (hay fever), some forms of 
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asthma, urticaria and anaphylactic shock. But, there are 
other incentives for the occurrence of IgE independent mast 
cell degranulation. Basophils also represents 15% of 
infiltrate cells in allergic dermatitis and skin alograf 
rejection, known as basophils skin hypersensitivity, 
induced by sensitized lymphocytes and is a kind of 
hypersensitivity with media of slow degranulation cells 
(Burkitt et al. 1995). 
Because the MCFAs contained in the VCO are 
particularly monolaurin which can reduce protein 
catabolism in hiperkatabolik status and serve as a protein 
sparer which prevents oxidation of amino acids to produce 
energy, so it provides the supply the protein into tissue. The 
supply of tissue protein stimulates the secretion of 
glucagon which activates adenil cyclase, produces cyclic 
AMP; so, the phosphorylation for metabolism processes of 
cell is activated normally, such as gland secretion and 
activity of enzymes, hormones, or repairing their receptors 
(Guyton and Hall 2008). The repair of hormones activity is, 
among other, increasing the sensitivity of receptors that 
they will have the ability to actively induce immunological 
response toward the Th1-Th2 balance after being exposed 
to ovalbumin allergen. According to Endaryanto and 
Harsono (1996), allergic is a form of Th2 disease which its 
cure requires the patient to be on a balanced condition 
between Th1 and Th2. So if risk factors cannot be avoided 
for the prevention, active induction of immunological 
response toward Th1-Th2 balance needs to be strived. 
According to Abbas and Lichtman (2004), allergy is a type 
of pathological reactions caused by the release of mediators 
from mast cells. Generally, the production of IgE antibody 
cells mast is in various tissues of the body. The situation is 
followed by inflammation in some individuals exposed by 
certain foreign antigens which have hit them before. 
Basically, the immune response, whether specific or 
nonspecific, is to act protectively. But the immune response 
can lead to bad consequences and even disease called 
hypersensitivity. In addition, according to Bratawidjaja 
(2004), levels of cAMP and cGMP in cells are one of the 
things that affect of degranulation of mast cell. The 
increase of cAMP prevents degranulation, while moderate 
increase in cGMP boosts the prevention. So normally the 
percentage of basophiles is in the groups protected by 
VCO, although they were sensitized with ovalbumin, they 
allegedly did not experience an allergic event, this was due 
to the prevention of degranulation of basophiles due to the 
increase in AMP cyclic caused by the provision of VCO. 
The role of monocytes and eosinophils are not needed 
specifically on this group, because this study allegedly has 
no relation to bacteria and the given ovalbumin gives no 
result in anaphylactic reaction. According to Burkitt et al. 
(1995), the role of eosinophils are, among others, to destroy 
parasites, to respond to bacterial products and as 
complement components, especially a substance released 
by basophiles namely histamine and eosinophil 
chemotactic factor of anaphylaxis other than activated 
lymphocytes, the percentage of eosinophils in this group 
which was just below normal indicates high rates balance 
toward percentage of lymphocytes. 
Measurements of blood creatinine levels  
The average data of blood creatinine levels of each 
group is presented in Table 3. The data is then compared 
with the standard normal creatinine levels in mice by 
Jacoby and Fox (1984). From the measurement results of 9 
groups of mice, it was found that all group had a magnitude 
of blood creatinine levels between 0.320 to 0.5040 mg/dl 
which still meet the range of normal numbers by Jacoby 
and Fox (1984), namely 0.21 to 0.74 mg/dl.  
Tabel 2. The mean percentage of the types of leukocytes from all groups of Mus musculus (mice), day 37 (last day of the study) after 
treatment of a variety of healers and ovalbumin sensitization 
 
Treatment group Number of cells ( % ) Neutrophils  Lymphocytes Monocytes Eosinophils Basophils 
Non alloxan 
A 1.140-- 90.760++ 1.520* 0.220* 3.000++
B 4.460-- 88.920+ 0.920* 0.520* 3.760++
C 1.580-- 95.580++ 1.920* 0.200* 0.480*
D 2.600-- 93.580++ 4.580++ 0.060- 0.760*
Alloxan 
E 3.220- 94.540++ 0.820* 0.260* 0.460*
F 5.480- 82.120* 1.420* 0.140- 6.420++
G 0.860-- 95.460++ 1.180* 0.200* 0.060*
H 10.100* 85.800+ 1.200* 0.120- 0.580*
I 0.820-- 97.720++- 1.420* 0.140- 0.240*
Standard normal 
J 12-30 55-85 1-12 0.2-4.0 - 
K 6.7-37.2 63-75 0.7-2.6 0.9-3.8 0-1.5 
Note: Description of A to I are similar to Table 1. J. The normal according to Smith dan Mangkoewidjojo (1988). K. J. The normal 
according to Jacoby and Fox (1984). +: Greater than normal according to Smith and Mangkoewidjojo (1988) / Jacoby and Fox (1984) or 
both. -: Smaller than normal according to Smith and Mangkoewidjojo (1988) / Jacoby and Fox (1984) or both. *: Fulfilling the normal 
range according to Smith and Mangkoewidjojo (1988) / Jacoby and Fox (1984) or both. 
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Table 3. Mean blood creatinine levels of all treated groups on day 
37 (end of study) 
 
Treatment group Blood creatinine levels (mg/dl) 











 Standard normal  
J 0.21-0.74 
Note: Description of A to I are similar to Table 1. J. The normal 
according to Jacoby and Fox (1984).  
 
Giving VCO with a dose of 0.002 mL/35 g BW and 
0.0030 mL/35 g BW orally for 34 days (started on day 4th- 
37th), which is intended to lower blood glucose levels for 
groups of hyperglycemia mice and to protect the body 
against allergic reactions for groups of normoglycemia 
mice or groups that hyperglycemia does not affect the 
increase in blood creatinine levels. The increased value of 
creatinine would indicate a decrease of excretion, for 
example due to the decrease of kidney function. Thus, 
plasma creatinine values which are still within the normal 
range after long-term consumption of this VCO do not 
damage the kidneys, thus it is safe for consumption even 
though for a long-term consumption. This is appropriate 
with Kabara’s opinion (1978) that after consumption, the 
high percentage of lauric acid contained in the VCO which 
is a medium chain saturated fat will come into the digestive 
tract and can be easily absorbed without enzymatic process, 
thus more quickly reach the bloodstream. Furthermore, 
through blood flow it is brought to liver (heart) and to other 
tissues directly into mitochondria without the need for 
carnitine, and then will be converted into energy (ATP), so 
it will not be accumulated as fat that can lead to problems 
of blood vessels, etc.. Lauric acid is the most important 
fatty acids in VCO which potentially build and maintain 
the immune system. According to him, coconut oil improve 
immune system, among others, by lowering the amount of 
H4 virus and increase the number of CD4 cell without the 
side effects that are concluded from various clinical tests, 
among others, the number of blood cells, liver function 
tests (ALT and AST), renal function tests (urea and 
creatinine), blood lipids (cholesterol, triglycerides, HDL) 
and body weight. 
 CONCLUSION  
Giving VCO (Virgin Coconut Oil), 0.003 mL per oral 
after 18 days can lower blood glucose levels of Mus 
musculus Balb/c with hyperglycemia. The leukocyte 
differential of mice with hyperglycemia in this study: 
3.220% of neutrophil, lymphocytes: 94.540%, 0.820%, of 
monocytes, eosinophils: 0.260%, 0.460% of basophile, 
which reflects the low percentage of neutrophil and the 
high percentage of lymphocytes. Giving VCO onto 
differential of mice leukocyte which are exposed to 
ovalbumin will normalize the percentage of basophils. 
Giving VCO to differential of hyperglycemic mice 
leukocyte which are exposed to ovalbumin can normalize 
the percentage of basophils and neutrophils. 
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